Double-Phase Tc-99m MIBI Scintigraphy as a Therapeutic Predictor in Patients with Non-Hodgkin's Lymphoma

Clinical Nuclear Medicine

Volumn 28, Issue 6, 2003, Pages 457-462

  Song, Ho Chun ^a   Lee, Je Jung ^a   Bom, Hee Seung ^a   Chung, Ik Joo ^a   Kim, Hyeoung Joon ^a   Park, Young Kyu ^b   Kim, E Edmund ^c  

^a Chonnam National University Medical School   (South Korea)

^b Seonam University   (South Korea)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Non Hodgkin's Lymphoma; Response; Tc 99m MIBI

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; LACTATE DEHYDROGENASE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PREDNISOLONE; VINCRISTINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SCINTISCANNING; CANCER SIZE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; HUMAN; IMAGING SYSTEM; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; NONHODGKIN LYMPHOMA; PREDICTION; PROGNOSIS; SCINTIGRAPHY; TREATMENT OUTCOME; BLOOD; MIDDLE AGED; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; SCINTISCANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; TREATMENT OUTCOME;

EID: 0042735300     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-200306000-00001     Document Type: Article

References (36)

1. Armitage JO, Mauch PM, Harris NL, et al: Non-Hodgkin's lymphoma. In: DeVita VT Jr, ed. Cancer: Principle and Practice of Oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001, pp 2256-2316.
2. Hiddemann W: Non-Hodgkin's lymphomas: current status of therapy and future perspectives. Eur J Cancer 31A:2141, 1995.
3. Hochhauser D, Harris AL: Drug resistance. Br Med Bull 47:178, 1991.
4. Nooter K, Sonneveld P: Multidrug resistance (MDR) genes in haematological malignancies. Cytotechnology 12:213, 1993.
5. Webb M, Brun M, McNiven M, et al: MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders. Br J Haematol 102:710, 1998.
6. Pileri SA, Sabattini E, Falini B, et al: Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology 19:131, 1991.
7. Rodriguez C, Commes T, Robert J, et al: Expression of P-glycoprotein and anionic glutathione S-transferase genes in non-Hodgkin's lymphoma. Leuk Res 17:149, 1993.
8. Liu Q, Ohshima K, Kikuchi M: High expression of MDR-1 gene and P-glycoprotein in initial and re-biopsy specimens of relapsed B-cell lymphoma. Histopathology 38:209, 2001.
9. Dan S, Esumi M, Sawada U, et al: Expression of a multidrug-resistance gene in human malignant lymphoma and related disorders. Leuk Res 15:1139, 1991.
10. Piwnica-Worms D, Chiu ML, Budding M, et al: Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53:977, 1993. 99m-sestamibi. J Nucl Med 35:510, 1994.
11. Piwnica-Worms D, Chiu ML, Budding M, et al: Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53:977, 1993. 99m-sestamibi. J Nucl Med 35:510, 1994.
12. Rao VV, Chiu ML, Kronauge JF, et al: Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi. J Nucl Med 35:510, 1994.
13. Moretti JL, Duran Cordobes M, Starzec A, et al: Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells. J Nucl Med 39:1214, 1998.
14. Kostakoglu L, Guc D, Canpinar H, et al: P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy. J Nucl Med 39:1191, 1998.
15. Shih WJ, Rastogi A, Stipp V, et al: Functional retention of Tc-99m MIBI in mediastinal lymphomas as a predictor of chemotherapeutic response demonstrated by consecutive thoracic SPECT imaging. Clin Nucl Med 23:505, 1998.
16. Kapucu LO, Akyuz C, Vural G, et al: Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi. J Nucl Med 38:243, 1997.
17. Kao CH, Tsai SC, Wang JJ, et al: Evaluation of chemotherapy response using technetium-99m-sestamibi scintigraphy in untreated adult malignant lymphomas and comparison with other prognosis factors: a preliminary report. Int J Cancer 95:228, 2001.
18. Kao CH, Tsai SC, Wang JJ, et al: Technetium-99m-sestamethoxy-isobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression, multidrug resistance-related protein expression and other prognosis factors. Br J Haematol 113:369, 2001.
19. Matsui R, Komori T, Narabayashi I, et al: Tc-99m sestamibi uptake by malignant lymphoma and slow washout. Clin Nucl Med 20:352, 1995.
20. Yoon JH, Bom HS, Song HC, et al: Double-phase Tc-99m sestamibi scintimammography to assess angiogenesis and P-glycoprotein expression in patients with untreated breast cancer. Clin Nucl Med 24:314, 1999.
21. Waxman AD: Thallium-201 and technetium-99m methoxyisobutyl isonitril (MIBI) in nuclear oncology. In: Sandler MP, ed. Diagnostic Nuclear Medicine, 3rd ed. Baltimore: Williams & Wilkins, 1996, pp 1261-74.
22. Ross EM: Pharmacodynamics: Mechanisms of drug action and the relationship between drug concentration and effect. In: Hardman JG, ed. The Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill, 1996, pp 29-41.
23. Gottesman MM, Pastan I: The multidrug transporter, a double-edged sword. J Biol Chem 263:12163, 1988.
24. Endicott JA, Ling V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58:137, 1989.
25. Croop JM, Gros P, Housman DE: Genetics of multidrug resistance. J Clin Invest 81:1303, 1988.
26. Kim M, Gronda MV, Messner HA, et al: Accumulation of sestamibi in lymphoma cell lines in vitro. Leuk Lymphoma 38:599, 2000.
27. 99mTc-MIBI scintimammography. Ann Nucl Med 12:307, 1998.
28. Salles G: Towards new prognostic factors in diffuse large cell non-Hodgkin's lymphoma. Ann Oncol 7:993, 1996.
29. Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 16:2780, 1998.
30. Blay J, Gomez F, Sebban C, et al: The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 92:3562, 1998.
31. Hermans J, Krol AD, van Groningen K, et al: International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 86:1460, 1995.
32. Nabholtz JM, Friedman S, Bastien H, et al: A clinico-pathological and prognostic analysis of non-Hodgkin lymphoma. A study of 203 patients. Acta Oncol 27:489, 1988.
33. Lopez-Guillermo A, Montserrat E, Reverter JC, et al: Large-cell lymphoma: a study of prognostic factors and assessment of five recently proposed predictive systems. Leuk Lymphoma 10:101, 1993.
34. Pasquini E, Nicolini M, Rosti G, et al: Prognostic factors and survival in non-Hodgkin's lymphomas: the experience of the Istituto Oncologico Romagnolo (IOR). Leuk Lymphoma 14: 475, 1994.
35. Maurea S, Acampa W, Varrella P, et al: Tc-99m sestamibi imaging in the diagnostic assessment of patients with lymphomas: comparison with clinical and radiological evaluation. Clin Nucl Med 23:283, 1998.
36. Ziegels P, Nocaudie M, Huglo D, et al: Comparison of technetium-99m methoxyisobutylisonitrile and gallium-67 citrate scanning in the assessment of lymphomas. Eur J Nucl Med 22:126, 1995.